________________________________________________________
________________________________________________________
The story of cancer therapy has a dividing line.
Therapies once were blunt instruments - knives and poisons. Cancers would be taken out by surgery, radiation and chemotherapy, only to return months or years later.
But about two decades ago, a few scientists, understanding how cancer works at the molecular level, discovered targeted therapies and immunotherapy. They harnessed the immune system to chase down malignant cells. Some cancers were cured, others became diseases to be managed.
Knowing that oncology is about to take another leap, Cancer Focus Fund selects first-in-kind-treatments that are moving down new biological pathways to take out stubborn cancers. Drugs in our portfolio block multiple immune checkpoints, or target overexpressed proteins on malignancies, or strike cancer cells just when they begin to repair their own DNA.
Our goal: Cancer will no longer have the final word.
ImmunoGenesis is an immuno-oncology biopharmaceutical company re-envisioning “cold” tumor treatment.
March Biosciences is a clinical-stage company in the cell therapy field focused on developing CAR-T cell strategies to address the most challenging hematological cancers.
ISA Pharmaceuticals is a clinical stage biotech company developing immunotherapies to treat cancers and infectious diseases.
Mereo BioPharma (NASDAQ: MREO) is a publicly traded San Diego and London-based biotech developing and commercializing new therapies for oncology and rare disease.
Eisbach Bio is a clinical-stage biotechnology company focused on precision oncology, aiming to disrupt tumor growth by targeting genetic vulnerabilities.
KAHR is a private clinical stage company based in Israel developing innovative immune-recruitment cancer drugs that activate immune responses by converting cancer camouflage into beacons for the immune system to attack.
Nectin Therapeutics is a biotechnology company developing novel targeted immunotherapies that address resistance to approved immune oncology treatments.
